Immunotherapy: New or second CARs for ALL – Nature.com
|
Immunotherapy: New or second CARs for ALL
Nature.com Anti-CD19 chimeric antigen receptor (CAR) T cells have remarkable clinical activity against B-cell acute lymphoblastic leukaemia (B-ALL); indeed, the first approval of such agents was for this disease. Nevertheless, relapses can occur, often owing to … |
